Dianthus Therapeutics presents autoimmune pipeline advances in June 2026 update
Dianthus Therapeutics released an investor presentation highlighting its autoimmune-focused pipeline, featuring two lead candidates: claseprubart and DNTH212, both in clinical development. The company outlined clinical trial plans and market opportunities for complement therapies, though both compounds remain investigational and unapproved.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day